Gardasil sales sink further Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 24 April, 2025

Exploring Japan as a key market for your drug? Get the roadmap — join senior Japanese leaders to hear firsthand on the regulatory and pricing dynamics behind one of the world’s top pharma markets. Sign up now.

presented by AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

news Roche takes steps to protect itself from tariffs, while Sanofi hangs back •  Roche CEO warns that tariffs could impact dealmaking Merck’s Gardasil sales sink further amid China market pressure Thermo Fisher buckles up for US-China trade war, budgets $2B to ease impact Sanofi's Altuviiio closing in on blockbuster status, Dupixent sales surge Bristol Myers' transition moves forward as it raises 2025 revenue forecast

VP, Clinical Development / CMO / CDO‬ Autonomy Bio Inc. San Francisco, CA 94107, USA COO / Head of Operations Autonomy Bio Inc. San Francisco, CA 94107, USA ‭ Regulatory Lead / Head of Regulatory‬ Autonomy Bio Inc. San Francisco, CA 94107, USA Senior Drug Development Clinician Weatherden London, UK Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Join us as we break down the latest oncology data, spotlight standout pipelines, and explore what’s coming next — reserve your spot today.

endpoints pharma China’s biotech market is staging a comeback that US biotech can only wish for AstraZeneca CEO says Europe is 'falling behind' on R&D and manufacturing investments Top pharma companies increased lobbying spend in first quarter of 2025 Large vaccine makers stand by their investments despite US headwinds

in case you missed it 1. With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief 2. FDA asks Novavax for post-marketing data of its Covid vaccine, delaying approval 3. Genentech vet launches ADC startup with $20M 4. Bristol Myers' schizophrenia drug fails Phase 3 trial for adjunctive treatment 5. Ascletis posts puzzling Phase 1 update on obesity pill 6. Akeso reports another Phase 3 win for PD-1xVEGF approach in lung cancer